东北制药(000597) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the period was ¥1,763,434,817.79, representing a decrease of 9.01% year-on-year[9] - Net profit attributable to shareholders was a loss of ¥57,400,936.91, a decline of 201.80% compared to the same period last year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥91,309,841.69, down 267.55% year-on-year[9] - Basic earnings per share were -¥0.0425, a decrease of 201.67% year-on-year[9] - The company reported a net profit of ¥404,649,756.69, slightly up from ¥403,837,857.26, indicating a marginal increase of 0.2%[47] - The net profit for the current period is -¥60,542,527.55, compared to a net profit of ¥61,474,686.58 in the previous period, indicating a significant decline[61] - The company reported a comprehensive income total of CNY -147,682,386.51 for the quarter, compared to CNY -46,432,624.35 in the previous year[69] - The company reported a total profit (loss) for the current period is CNY -122,498,424.53, compared to CNY 243,766,446.66 in the previous period[81] Assets and Liabilities - Total assets at the end of the reporting period reached ¥13,021,244,796.07, an increase of 3.84% compared to the end of the previous year[9] - Total liabilities reached ¥8,910,675,491.34, up from ¥8,622,000,586.02, which is an increase of about 3.34%[45] - Owner's equity increased to ¥4,110,569,304.73 from ¥3,917,828,400.92, showing a growth of approximately 4.92%[47] - Current liabilities totaled ¥8,157,282,909.29, compared to ¥7,899,248,227.72, indicating an increase of approximately 3.27%[45] - The total liabilities amount to ¥5,331,336,444.25, a slight decrease from ¥5,464,201,152.12 in the previous period[53] - The company reported a total asset value of 12,539,828,986.94 CNY, unchanged from the previous period, indicating stability in asset management[100] - The total liabilities amounted to 7,899,248,227.72 CNY, consistent with the previous period, suggesting no significant changes in debt levels[103] Cash Flow - Net cash flow from operating activities was ¥305,977,403.48, an increase of 816.28% compared to the same period last year[9] - The ending balance of cash and cash equivalents is CNY 199,233,000, an increase of 31% compared to the beginning of the year, primarily due to increased cash flow from operating activities[22] - The net cash flow from operating activities is CNY 462,788,965.54, a significant improvement from a negative cash flow of CNY -174,688,953.07 in the previous period[87] - Cash inflow from financing activities totaled 3,502,116,626.46 CNY, significantly higher than 2,411,835,159.47 CNY in the prior period, reflecting increased borrowing[96] - The net cash flow from financing activities was 744,642,339.09 CNY, up from 479,787,135.68 CNY, indicating stronger financing support[96] Research and Development - Research and development expenses for the period amount to CNY 4,576,000, an increase of 37% year-on-year, attributed to increased R&D investments[22] - Research and development expenses for the current period are ¥10,611,303.78, an increase from ¥6,198,242.92 in the previous period, indicating a focus on innovation[64] - Research and development expenses increased to CNY 45,763,763.14, up 36.5% from CNY 33,511,045.54 year-on-year[70] - Research and development expenses increased to CNY 36,017,154.30, up from CNY 18,516,203.32, reflecting a 95% increase year-over-year[81] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,208[12] - The largest shareholder, Liaoning Fangda Group Industrial Co., Ltd., held 24.35% of the shares, totaling 329,068,713 shares[13] Government Support - The company received government subsidies amounting to ¥49,901,938.62 during the reporting period[9]